Obermatt
See Similar Stocks →

MIRA Pharmaceuticals

NAQ:MIRA · US60458C1045
PharmaceuticalsX-Small

360° View

no current rank
Price/Sales—
Price/Earnings—
Price/Book24
Dividend Yield1
Revenue Growth—
Profit Growth27
Capital Growth33
TSR 52w18
Leverage56
Liquidity—
Refinancing62
Combined—
Analyst Opinions—
Pro Holdings7
Opinion Changes—
Market Pulse41

Profile

CountryUSA
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeNASDAQCM
Founded2020
Employees7
Websitemirapharmaceuticals.com
ISINUS60458C1045
Last UpdateApr 2, 2026
Index & Theme
Pain ManagementObesityDiabetesNeurologyNeuroscienceCentral Nervous SystemChronic DiseasesCannabisPsychiatryHealth CareMedicalPharmaceutical

Description

MIRA Pharmaceuticals, Inc. (MIRA) operates as a clinical-stage pharmaceutical development company with two neuroscience programs targeting neurologic and neuropsychiatric disorders. The company holds exclusive rights in the U.S., Canada, and Mexico…

Similar Stocks

The companies this stock is ranked against.

Compare MIRA Pharmaceuticals with its peers
Vericel
NMQ:VCEL
82
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
NRX Pharmaceuticals
NAQ:NRXP
49
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Neumora Therapeutics
NSQ:NMRA
9
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Grace Therapeutics
NAQ:GRCE
52
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Trevi Therapeutics
NMQ:TRVI
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →